AdaptHealth’s Debt Fix Hides Q2 Profitability Test

Forward-Looking Analysis

Wall Street analysts forecast AdaptHealth’s Q2 2026 Earnings Per Share (EPS) at an average estimate of $0.17, with a single analyst providing this projection. This represents a significant turnaround from the Q4 2025 reported EPS of -$0.76, which missed the consensus estimate of $0.34 by $1.10. The company issued full-year 2026 financial guidance on May 5, 2026, projecting net revenue between $3.44 billion and $3.51 billion, aligning with the consensus revenue estimate of $3.5 billion. For the full year, Adjusted EBITDA is guided between $680 million and $730 million, with free cash flow expected to range from $175 million to $225 million. Analyst sentiment remains positive, with five Wall Street analysts covering the stock issuing a consensus "Strong Buy" rating. The average 12-month price target is set at $13.40, implying a potential upside of 53.14% from recent trading levels, with a price target range spanning from $11.00 to $16.00. Earnings are projected to grow substantially, with forecasts indicating a 140.91% increase in EPS over the next year, rising from $0.44 to $1.06 per share. However, revenue growth is expected to be more modest, with a forecast annual revenue growth rate of 4.12% for 2026-2028, which trails the US Medical Devices industry average of 7.71% and the broader US market average of 11.03%.

Historical Performance Review

AdaptHealth delivered mixed results in Q1 2026, reporting revenue of $819.80 million against a gross profit of $111.50 million. The quarter was characterized by profitability challenges, as the company posted a net income loss of $-14.87 million and an EPS of $-0.12. These figures contrast with the previous year's trajectory, highlighting ongoing operational headwinds despite the company's efforts to optimize its cost structure. The negative net income and EPS indicate that while top-line revenue was maintained, margin compression or increased expenses impacted the bottom line, underscoring the importance of the upcoming Q2 results in demonstrating a path toward sustained profitability.

Additional News

In a significant financial milestone, AdaptHealth closed a $1.1 billion senior secured credit facility on April 13, 2026. This new facility, comprising a $325M Term Loan, $325M Delayed Draw Term Loan, and $450M Revolver, extends the company's debt maturity to April 2031. The refinancing reduces the weighted average cost of debt by at least 25 basis points, lowering the lowest pricing tier from 1.50% to 1.125% over SOFR, thereby enhancing financial flexibility. This move follows credit rating upgrades from major agencies, signaling improved creditworthiness. In November 2025, S&P upgraded its senior unsecured debt rating to BB- from B+, citing a $225 million reduction in Term Loan A funded by free cash flow and asset dispositions. Subsequently, in January 2026, Moody’s upgraded its Corporate Family Rating to Ba2 from Ba3. These upgrades reflect the company's disciplined focus on debt reduction and operational efficiency, supporting its strategic goal of strengthening its balance sheet while continuing to serve approximately 4.3 million patients annually across its four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home.

Summary & Outlook

AdaptHealth demonstrates improving financial health through successful debt refinancing and credit upgrades, despite recent quarterly net losses. The primary growth catalyst is the execution of its 2026 guidance targeting $680-$730 million in Adjusted EBITDA, driven by operational efficiencies and capitated agreements. However, revenue growth forecasts lag industry peers, presenting a risk to top-line expansion. The company's ability to convert operational improvements into consistent EPS growth remains critical. Given the strong analyst consensus and improved liquidity, the outlook is cautiously bullish, contingent on Q2 2026 results validating the path to sustained profitability and debt reduction targets.